Antihypertensive effects of androgens in conscious, spontaneously hypertensive rats

•Androgen-induced direct decrease in systemic blood pressure in rats with hypertension.•Androgens play a significant role in the control of blood pressure and may contribute to the pathogenesis of hypertension.•A blockade of L-VOCC may be involved in the antihypertensive effects of androgens.•Testos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of steroid biochemistry and molecular biology 2017-03, Vol.167, p.106-114
Hauptverfasser: Perusquía, Mercedes, Herrera, Nieves, Ferrer, Mercedes, Stallone, John N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 114
container_issue
container_start_page 106
container_title The Journal of steroid biochemistry and molecular biology
container_volume 167
creator Perusquía, Mercedes
Herrera, Nieves
Ferrer, Mercedes
Stallone, John N.
description •Androgen-induced direct decrease in systemic blood pressure in rats with hypertension.•Androgens play a significant role in the control of blood pressure and may contribute to the pathogenesis of hypertension.•A blockade of L-VOCC may be involved in the antihypertensive effects of androgens.•Testosterone deprivation by orchidectomy may be a factor responsible for the development of hypertension, and testosterone replacement therapy may prevent these increases in blood pressure. Androgens are vasoactive steroids that induce acute vasodilation in a number of isolated vascular beds from different species, but the effects of these hormones on systemic blood pressure (BP) have been studied little. Although it has been reported that androgens exert systemic hypotensive effects through peripheral vasodilation in normotensive rats, there have not been any reports of systemic hypotensive effects of androgens in animals with hypertension. This study was designed to evaluate the acute effects of testosterone (TES) and its 5-reduced metabolites on systemic BP in hypertensive rats and to test the hypothesis that hypotestosteronemia may be involved in the pathogenesis of hypertension. Chronic, indwelling catheters were implanted in carotid artery and jugular vein of 18–21-week-old male spontaneously hypertensive rats (SHR) and normotensive-control Wistar-Kyoto (WKY) rats, for BP recording and drug administration, respectively. Bolus injections of TES, 5α- or 5β-dihydrotestosterone (5α- and 5β-DHT), were administrated cumulatively to conscious rats at doses of 0.1–100μmolkg−1min−1. 5β-DHT was also administrated during the pressor effect of Bay K 8644, an L-type voltage-operated Ca2+ channel (L-VOCC) agonist. In separate experiments, BP of orchidectomized normotensive male WKY and Wistar rats, with or without androgen-replacement therapy, was evaluated weekly for 10 weeks by tail-cuff plethysmography. TES and its metabolites reduced BP in a dose-dependent manner, while heart rate was reduced with some androgens at the highest doses. The hypotensive effects of androgens were markedly greater in SHR, with a rank order potency of: 5β-DHT>TES>5α-DHT. 5β-DHT, the most potent antihypertensive androgen, abolished the pressor response to Bay K 8644 in SHR. TES deprivation by orchidectomy increased BP in normotensive WKY and Wistar rats, but this hypertension was prevented by TES replacement therapy. BP responses to androgens are androgen structure-dependent. These data indicate
doi_str_mv 10.1016/j.jsbmb.2016.11.016
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1844031032</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960076016303302</els_id><sourcerecordid>1979951411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-fcc8d87772f302c5247f5013d68d9a9e297dba444ff860c3b11568c9198b77fb3</originalsourceid><addsrcrecordid>eNp9kE1LxDAURYMoOn78AkEKblzYmpe0TbJwMQx-geBCXYc2TTRlJhmTdmD-vdFRQReuLi-c-_I4CB0DLgBDfdEXfWwXbUHSUAAUKbbQBDgTORCCt9EEixrnmNV4D-3H2GOMKQW2i_YI45wDrSboceoG-7pe6jBoF-1KZ9oYrYaYeZM1rgv-Jb1n1mXKu6isH-N5FpfeDY3TaZivs1_t0AzxEO2YZh710VceoOfrq6fZbX7_cHM3m97ninI25EYp3nHGGDEUE1WRkpkKA-1q3olGaCJY1zZlWRrDa6xoC1DVXAkQvGXMtPQAnW32LoN_G3Uc5MJGpefzzWkSeFliCpiShJ7-QXs_BpeukyCYEBWUAImiG0oFH2PQRi6DXTRhLQHLD-eyl5_O5YdzCSBTpNbJ1-6xXejup_MtOQGXG0AnGSurg0witVO6syGplp23_37wDsb1k9k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1979951411</pqid></control><display><type>article</type><title>Antihypertensive effects of androgens in conscious, spontaneously hypertensive rats</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Perusquía, Mercedes ; Herrera, Nieves ; Ferrer, Mercedes ; Stallone, John N.</creator><creatorcontrib>Perusquía, Mercedes ; Herrera, Nieves ; Ferrer, Mercedes ; Stallone, John N.</creatorcontrib><description>•Androgen-induced direct decrease in systemic blood pressure in rats with hypertension.•Androgens play a significant role in the control of blood pressure and may contribute to the pathogenesis of hypertension.•A blockade of L-VOCC may be involved in the antihypertensive effects of androgens.•Testosterone deprivation by orchidectomy may be a factor responsible for the development of hypertension, and testosterone replacement therapy may prevent these increases in blood pressure. Androgens are vasoactive steroids that induce acute vasodilation in a number of isolated vascular beds from different species, but the effects of these hormones on systemic blood pressure (BP) have been studied little. Although it has been reported that androgens exert systemic hypotensive effects through peripheral vasodilation in normotensive rats, there have not been any reports of systemic hypotensive effects of androgens in animals with hypertension. This study was designed to evaluate the acute effects of testosterone (TES) and its 5-reduced metabolites on systemic BP in hypertensive rats and to test the hypothesis that hypotestosteronemia may be involved in the pathogenesis of hypertension. Chronic, indwelling catheters were implanted in carotid artery and jugular vein of 18–21-week-old male spontaneously hypertensive rats (SHR) and normotensive-control Wistar-Kyoto (WKY) rats, for BP recording and drug administration, respectively. Bolus injections of TES, 5α- or 5β-dihydrotestosterone (5α- and 5β-DHT), were administrated cumulatively to conscious rats at doses of 0.1–100μmolkg−1min−1. 5β-DHT was also administrated during the pressor effect of Bay K 8644, an L-type voltage-operated Ca2+ channel (L-VOCC) agonist. In separate experiments, BP of orchidectomized normotensive male WKY and Wistar rats, with or without androgen-replacement therapy, was evaluated weekly for 10 weeks by tail-cuff plethysmography. TES and its metabolites reduced BP in a dose-dependent manner, while heart rate was reduced with some androgens at the highest doses. The hypotensive effects of androgens were markedly greater in SHR, with a rank order potency of: 5β-DHT&gt;TES&gt;5α-DHT. 5β-DHT, the most potent antihypertensive androgen, abolished the pressor response to Bay K 8644 in SHR. TES deprivation by orchidectomy increased BP in normotensive WKY and Wistar rats, but this hypertension was prevented by TES replacement therapy. BP responses to androgens are androgen structure-dependent. These data indicate that: 1) androgens play a significant role in the control of BP and may contribute to the pathogenesis of hypertension; 2) blockade of L-VOCC is involved in the antihypertensive effects of androgens, which are non-genomically mediated; and 3) hypotestosteronemia may be a risk factor for hypertension.</description><identifier>ISSN: 0960-0760</identifier><identifier>EISSN: 1879-1220</identifier><identifier>DOI: 10.1016/j.jsbmb.2016.11.016</identifier><identifier>PMID: 27888135</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>5α-Dihydrotestosterone ; 5β-Dihydrotestosteronea ; Acute effects ; Androgens ; Androgens - pharmacology ; Animals ; Antihypertensive Agents - pharmacology ; Antihypertensive response ; Antihypertensives ; Blood pressure ; Blood Pressure - drug effects ; Blood pressure regulation ; Calcium ; Calcium channels (L-type) ; Calcium channels (voltage-gated) ; Calcium Channels, L-Type - metabolism ; Carotid artery ; Catheters ; Consciousness - drug effects ; Dihydrotestosterone ; Dihydrotestosterone - pharmacology ; Effects ; Heart rate ; Hormone replacement therapy ; Hypertension ; Hypertension - metabolism ; Hypertension - pathology ; Hypotension ; Jugular vein ; Male ; Metabolites ; Orchidectomy ; Orchiectomy ; Rats ; Rats, Inbred SHR ; Rats, Inbred WKY ; Rats, Wistar ; Risk Factors ; Steroid hormones ; Testosterone ; Testosterone - pharmacology ; Vasoactive agents ; Vasodilation</subject><ispartof>The Journal of steroid biochemistry and molecular biology, 2017-03, Vol.167, p.106-114</ispartof><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier BV Mar 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-fcc8d87772f302c5247f5013d68d9a9e297dba444ff860c3b11568c9198b77fb3</citedby><cites>FETCH-LOGICAL-c387t-fcc8d87772f302c5247f5013d68d9a9e297dba444ff860c3b11568c9198b77fb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0960076016303302$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27888135$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perusquía, Mercedes</creatorcontrib><creatorcontrib>Herrera, Nieves</creatorcontrib><creatorcontrib>Ferrer, Mercedes</creatorcontrib><creatorcontrib>Stallone, John N.</creatorcontrib><title>Antihypertensive effects of androgens in conscious, spontaneously hypertensive rats</title><title>The Journal of steroid biochemistry and molecular biology</title><addtitle>J Steroid Biochem Mol Biol</addtitle><description>•Androgen-induced direct decrease in systemic blood pressure in rats with hypertension.•Androgens play a significant role in the control of blood pressure and may contribute to the pathogenesis of hypertension.•A blockade of L-VOCC may be involved in the antihypertensive effects of androgens.•Testosterone deprivation by orchidectomy may be a factor responsible for the development of hypertension, and testosterone replacement therapy may prevent these increases in blood pressure. Androgens are vasoactive steroids that induce acute vasodilation in a number of isolated vascular beds from different species, but the effects of these hormones on systemic blood pressure (BP) have been studied little. Although it has been reported that androgens exert systemic hypotensive effects through peripheral vasodilation in normotensive rats, there have not been any reports of systemic hypotensive effects of androgens in animals with hypertension. This study was designed to evaluate the acute effects of testosterone (TES) and its 5-reduced metabolites on systemic BP in hypertensive rats and to test the hypothesis that hypotestosteronemia may be involved in the pathogenesis of hypertension. Chronic, indwelling catheters were implanted in carotid artery and jugular vein of 18–21-week-old male spontaneously hypertensive rats (SHR) and normotensive-control Wistar-Kyoto (WKY) rats, for BP recording and drug administration, respectively. Bolus injections of TES, 5α- or 5β-dihydrotestosterone (5α- and 5β-DHT), were administrated cumulatively to conscious rats at doses of 0.1–100μmolkg−1min−1. 5β-DHT was also administrated during the pressor effect of Bay K 8644, an L-type voltage-operated Ca2+ channel (L-VOCC) agonist. In separate experiments, BP of orchidectomized normotensive male WKY and Wistar rats, with or without androgen-replacement therapy, was evaluated weekly for 10 weeks by tail-cuff plethysmography. TES and its metabolites reduced BP in a dose-dependent manner, while heart rate was reduced with some androgens at the highest doses. The hypotensive effects of androgens were markedly greater in SHR, with a rank order potency of: 5β-DHT&gt;TES&gt;5α-DHT. 5β-DHT, the most potent antihypertensive androgen, abolished the pressor response to Bay K 8644 in SHR. TES deprivation by orchidectomy increased BP in normotensive WKY and Wistar rats, but this hypertension was prevented by TES replacement therapy. BP responses to androgens are androgen structure-dependent. These data indicate that: 1) androgens play a significant role in the control of BP and may contribute to the pathogenesis of hypertension; 2) blockade of L-VOCC is involved in the antihypertensive effects of androgens, which are non-genomically mediated; and 3) hypotestosteronemia may be a risk factor for hypertension.</description><subject>5α-Dihydrotestosterone</subject><subject>5β-Dihydrotestosteronea</subject><subject>Acute effects</subject><subject>Androgens</subject><subject>Androgens - pharmacology</subject><subject>Animals</subject><subject>Antihypertensive Agents - pharmacology</subject><subject>Antihypertensive response</subject><subject>Antihypertensives</subject><subject>Blood pressure</subject><subject>Blood Pressure - drug effects</subject><subject>Blood pressure regulation</subject><subject>Calcium</subject><subject>Calcium channels (L-type)</subject><subject>Calcium channels (voltage-gated)</subject><subject>Calcium Channels, L-Type - metabolism</subject><subject>Carotid artery</subject><subject>Catheters</subject><subject>Consciousness - drug effects</subject><subject>Dihydrotestosterone</subject><subject>Dihydrotestosterone - pharmacology</subject><subject>Effects</subject><subject>Heart rate</subject><subject>Hormone replacement therapy</subject><subject>Hypertension</subject><subject>Hypertension - metabolism</subject><subject>Hypertension - pathology</subject><subject>Hypotension</subject><subject>Jugular vein</subject><subject>Male</subject><subject>Metabolites</subject><subject>Orchidectomy</subject><subject>Orchiectomy</subject><subject>Rats</subject><subject>Rats, Inbred SHR</subject><subject>Rats, Inbred WKY</subject><subject>Rats, Wistar</subject><subject>Risk Factors</subject><subject>Steroid hormones</subject><subject>Testosterone</subject><subject>Testosterone - pharmacology</subject><subject>Vasoactive agents</subject><subject>Vasodilation</subject><issn>0960-0760</issn><issn>1879-1220</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAURYMoOn78AkEKblzYmpe0TbJwMQx-geBCXYc2TTRlJhmTdmD-vdFRQReuLi-c-_I4CB0DLgBDfdEXfWwXbUHSUAAUKbbQBDgTORCCt9EEixrnmNV4D-3H2GOMKQW2i_YI45wDrSboceoG-7pe6jBoF-1KZ9oYrYaYeZM1rgv-Jb1n1mXKu6isH-N5FpfeDY3TaZivs1_t0AzxEO2YZh710VceoOfrq6fZbX7_cHM3m97ninI25EYp3nHGGDEUE1WRkpkKA-1q3olGaCJY1zZlWRrDa6xoC1DVXAkQvGXMtPQAnW32LoN_G3Uc5MJGpefzzWkSeFliCpiShJ7-QXs_BpeukyCYEBWUAImiG0oFH2PQRi6DXTRhLQHLD-eyl5_O5YdzCSBTpNbJ1-6xXejup_MtOQGXG0AnGSurg0witVO6syGplp23_37wDsb1k9k</recordid><startdate>201703</startdate><enddate>201703</enddate><creator>Perusquía, Mercedes</creator><creator>Herrera, Nieves</creator><creator>Ferrer, Mercedes</creator><creator>Stallone, John N.</creator><general>Elsevier Ltd</general><general>Elsevier BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201703</creationdate><title>Antihypertensive effects of androgens in conscious, spontaneously hypertensive rats</title><author>Perusquía, Mercedes ; Herrera, Nieves ; Ferrer, Mercedes ; Stallone, John N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-fcc8d87772f302c5247f5013d68d9a9e297dba444ff860c3b11568c9198b77fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>5α-Dihydrotestosterone</topic><topic>5β-Dihydrotestosteronea</topic><topic>Acute effects</topic><topic>Androgens</topic><topic>Androgens - pharmacology</topic><topic>Animals</topic><topic>Antihypertensive Agents - pharmacology</topic><topic>Antihypertensive response</topic><topic>Antihypertensives</topic><topic>Blood pressure</topic><topic>Blood Pressure - drug effects</topic><topic>Blood pressure regulation</topic><topic>Calcium</topic><topic>Calcium channels (L-type)</topic><topic>Calcium channels (voltage-gated)</topic><topic>Calcium Channels, L-Type - metabolism</topic><topic>Carotid artery</topic><topic>Catheters</topic><topic>Consciousness - drug effects</topic><topic>Dihydrotestosterone</topic><topic>Dihydrotestosterone - pharmacology</topic><topic>Effects</topic><topic>Heart rate</topic><topic>Hormone replacement therapy</topic><topic>Hypertension</topic><topic>Hypertension - metabolism</topic><topic>Hypertension - pathology</topic><topic>Hypotension</topic><topic>Jugular vein</topic><topic>Male</topic><topic>Metabolites</topic><topic>Orchidectomy</topic><topic>Orchiectomy</topic><topic>Rats</topic><topic>Rats, Inbred SHR</topic><topic>Rats, Inbred WKY</topic><topic>Rats, Wistar</topic><topic>Risk Factors</topic><topic>Steroid hormones</topic><topic>Testosterone</topic><topic>Testosterone - pharmacology</topic><topic>Vasoactive agents</topic><topic>Vasodilation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perusquía, Mercedes</creatorcontrib><creatorcontrib>Herrera, Nieves</creatorcontrib><creatorcontrib>Ferrer, Mercedes</creatorcontrib><creatorcontrib>Stallone, John N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of steroid biochemistry and molecular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perusquía, Mercedes</au><au>Herrera, Nieves</au><au>Ferrer, Mercedes</au><au>Stallone, John N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antihypertensive effects of androgens in conscious, spontaneously hypertensive rats</atitle><jtitle>The Journal of steroid biochemistry and molecular biology</jtitle><addtitle>J Steroid Biochem Mol Biol</addtitle><date>2017-03</date><risdate>2017</risdate><volume>167</volume><spage>106</spage><epage>114</epage><pages>106-114</pages><issn>0960-0760</issn><eissn>1879-1220</eissn><abstract>•Androgen-induced direct decrease in systemic blood pressure in rats with hypertension.•Androgens play a significant role in the control of blood pressure and may contribute to the pathogenesis of hypertension.•A blockade of L-VOCC may be involved in the antihypertensive effects of androgens.•Testosterone deprivation by orchidectomy may be a factor responsible for the development of hypertension, and testosterone replacement therapy may prevent these increases in blood pressure. Androgens are vasoactive steroids that induce acute vasodilation in a number of isolated vascular beds from different species, but the effects of these hormones on systemic blood pressure (BP) have been studied little. Although it has been reported that androgens exert systemic hypotensive effects through peripheral vasodilation in normotensive rats, there have not been any reports of systemic hypotensive effects of androgens in animals with hypertension. This study was designed to evaluate the acute effects of testosterone (TES) and its 5-reduced metabolites on systemic BP in hypertensive rats and to test the hypothesis that hypotestosteronemia may be involved in the pathogenesis of hypertension. Chronic, indwelling catheters were implanted in carotid artery and jugular vein of 18–21-week-old male spontaneously hypertensive rats (SHR) and normotensive-control Wistar-Kyoto (WKY) rats, for BP recording and drug administration, respectively. Bolus injections of TES, 5α- or 5β-dihydrotestosterone (5α- and 5β-DHT), were administrated cumulatively to conscious rats at doses of 0.1–100μmolkg−1min−1. 5β-DHT was also administrated during the pressor effect of Bay K 8644, an L-type voltage-operated Ca2+ channel (L-VOCC) agonist. In separate experiments, BP of orchidectomized normotensive male WKY and Wistar rats, with or without androgen-replacement therapy, was evaluated weekly for 10 weeks by tail-cuff plethysmography. TES and its metabolites reduced BP in a dose-dependent manner, while heart rate was reduced with some androgens at the highest doses. The hypotensive effects of androgens were markedly greater in SHR, with a rank order potency of: 5β-DHT&gt;TES&gt;5α-DHT. 5β-DHT, the most potent antihypertensive androgen, abolished the pressor response to Bay K 8644 in SHR. TES deprivation by orchidectomy increased BP in normotensive WKY and Wistar rats, but this hypertension was prevented by TES replacement therapy. BP responses to androgens are androgen structure-dependent. These data indicate that: 1) androgens play a significant role in the control of BP and may contribute to the pathogenesis of hypertension; 2) blockade of L-VOCC is involved in the antihypertensive effects of androgens, which are non-genomically mediated; and 3) hypotestosteronemia may be a risk factor for hypertension.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>27888135</pmid><doi>10.1016/j.jsbmb.2016.11.016</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0960-0760
ispartof The Journal of steroid biochemistry and molecular biology, 2017-03, Vol.167, p.106-114
issn 0960-0760
1879-1220
language eng
recordid cdi_proquest_miscellaneous_1844031032
source MEDLINE; Elsevier ScienceDirect Journals
subjects 5α-Dihydrotestosterone
5β-Dihydrotestosteronea
Acute effects
Androgens
Androgens - pharmacology
Animals
Antihypertensive Agents - pharmacology
Antihypertensive response
Antihypertensives
Blood pressure
Blood Pressure - drug effects
Blood pressure regulation
Calcium
Calcium channels (L-type)
Calcium channels (voltage-gated)
Calcium Channels, L-Type - metabolism
Carotid artery
Catheters
Consciousness - drug effects
Dihydrotestosterone
Dihydrotestosterone - pharmacology
Effects
Heart rate
Hormone replacement therapy
Hypertension
Hypertension - metabolism
Hypertension - pathology
Hypotension
Jugular vein
Male
Metabolites
Orchidectomy
Orchiectomy
Rats
Rats, Inbred SHR
Rats, Inbred WKY
Rats, Wistar
Risk Factors
Steroid hormones
Testosterone
Testosterone - pharmacology
Vasoactive agents
Vasodilation
title Antihypertensive effects of androgens in conscious, spontaneously hypertensive rats
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T09%3A28%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antihypertensive%20effects%20of%20androgens%20in%20conscious,%20spontaneously%20hypertensive%20rats&rft.jtitle=The%20Journal%20of%20steroid%20biochemistry%20and%20molecular%20biology&rft.au=Perusqu%C3%ADa,%20Mercedes&rft.date=2017-03&rft.volume=167&rft.spage=106&rft.epage=114&rft.pages=106-114&rft.issn=0960-0760&rft.eissn=1879-1220&rft_id=info:doi/10.1016/j.jsbmb.2016.11.016&rft_dat=%3Cproquest_cross%3E1979951411%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1979951411&rft_id=info:pmid/27888135&rft_els_id=S0960076016303302&rfr_iscdi=true